Stay updated on Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page.

Latest updates to the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe webpage has undergone significant updates, including the addition of the study title 'Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin' and the revision number has been updated from v2.14.4 to v2.15.0. Additionally, the collaborators have been specified as Hoosier Cancer Research Network and Merck Sharp & Dohme LLC.SummaryDifference48%
- Check16 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 18, 2025.SummaryDifference0.2%
- Check24 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous estimated dates and version. This indicates a significant update to the content.SummaryDifference0.2%
- Check31 days agoChange DetectedThe webpage has been updated to include new results and timelines for a clinical study involving pembrolizumab, including specific metrics for safety, relapse-free survival, and overall survival. Key dates for results reporting have also been added.SummaryDifference9%
- Check60 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check74 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
Stay in the know with updates to Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page.